Julien Edeline

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Open-label Phase 2, Hepatology, Medicine +8

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle et al. · Journal of Clinical Oncology · 2019 · 1.8K citations

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

Thomas Yau, J.W. Park, Richard S. Finn et al. · Annals of Oncology · 2019 · 639 citations · Full text

Hepatology, Medicine, Checkmate 459 +9

Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial

Étienne Garin, Lambros Tselikas, Boris Guiu et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 568 citations

Open-label Phase 2, Radiation Therapy, Medicine +8